Press Releases
Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment
New Data Demonstrates Significant Reduction in Tumor Growth and KIT Expression in Preclinical GIST Models
